SCHEMBL25009200

SCHEMBL25009200

CC(C)S(=O)(=O)c1[nH]c(-c2ccccc2)nc1S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.52
TP53 P04637 6/20 0.52
SMN1; SMN2 Q16637 6/20 0.52
POLB P06746 2/20 0.49
LMNA P02545 4/20 0.46
HTT P42858 3/20 0.46
TSHR P16473 2/20 0.46
HSD17B10 Q99714 2/20 0.46
KDM4E B2RXH2 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
THRB P10828 2/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 1/20 0.40
MITF O75030 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25010255 0.86 LMNA (0.48) MAPTSMN1; SMN2LMNAHTTTSHR
SCHEMBL25009642 0.81 TP53 (0.43) MAPTTP53SMN1; SMN2POLBLMNA
SCHEMBL23416223 0.79 LMNA (0.44) MAPTTP53SMN1; SMN2POLBLMNA
SCHEMBL23416224 0.78 MAPT (0.35) MAPTTP53SMN1; SMN2POLBLMNA
SCHEMBL23416222 0.78 LMNA (0.41) MAPTTP53SMN1; SMN2POLBLMNA
SCHEMBL25009685 0.74 MAPK14 (0.41) TP53SMN1; SMN2CYP1A2CYP2C9ALDH1A1
SCHEMBL25009382 0.72 TSHR (0.42) MAPTTP53SMN1; SMN2POLBLMNA
SCHEMBL25011148 0.70 LMNA (0.40) MAPTTP53SMN1; SMN2POLBLMNA
SCHEMBL25009619 0.68 TP53 (1.00) MAPTTP53SMN1; SMN2POLBLMNA
SCHEMBL3023546 0.68 MAPT (0.53) MAPTTP53SMN1; SMN2POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230041576-A1 METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230041576-A1 METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY NFKBIA, IKBKB, NFKB2 MAPT 2111/4885TP53 376/4885SMN1; SMN2 2605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.